In this study, we examined the levels of CSF and plasma IL-37, IL-17A, IFN-γ, and TNF-α in 25 patients with new onset GBS before and after the standard therapy as well as 20 age- and gender-matched healthy controls. The gene discussed is IL17A; the disease is Guillain-Barre syndrome.